Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07452601) titled 'Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC' on Feb. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).

Primary Sponsor: Tang-Du Hospital

Condition: Esophageal Squamous Cell Carcinoma

Intervention: Drug: Adebrelimab plus nab-paclitaxel and cisplatin

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: February 25, 2026

Target Sample Size: 90

Countries of Recruitment: China

To know more, visit https://clinicaltrials.g...